Literature DB >> 33402194

Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.

Liying Ma1,2,3, Xing Bian1,2,3, Wenchu Lin4,5.   

Abstract

Entities:  

Year:  2021        PMID： 33402194      PMCID： PMC7783966          DOI： 10.1186/s13046-020-01805-6

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN： 0392-9078


× No keyword cloud information.
  1 in total

1.  The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.

Authors:  Liying Ma; Xing Bian; Wenchu Lin
Journal:  J Exp Clin Cancer Res       Date:  2020-10-17
  1 in total
  3 in total

1.  Dual Targeting of PI3K and HDAC by CUDC-907 Inhibits Pediatric Neuroblastoma Growth.

Authors:  Rameswari Chilamakuri; Saurabh Agarwal
Journal:  Cancers (Basel)       Date:  2022-02-20       Impact factor: 6.639

Review 2.  Histone deacetylases modulate resistance to the therapy in lung cancer.

Authors:  Estefanía Contreras-Sanzón; Heriberto Prado-Garcia; Susana Romero-Garcia; David Nuñez-Corona; Blanca Ortiz-Quintero; Cesar Luna-Rivero; Victor Martínez-Cruz; Ángeles Carlos-Reyes
Journal:  Front Genet       Date:  2022-10-03       Impact factor: 4.772

3.  Valeric acid acts as a novel HDAC3 inhibitor against prostate cancer.

Authors:  Rui Han; Hongxing Yang; Ya Li; Changquan Ling; Lingeng Lu
Journal:  Med Oncol       Date:  2022-09-29       Impact factor: 3.738
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.